UK markets closed
  • NIKKEI 225

    29,768.06
    +59.06 (+0.20%)
     
  • HANG SENG

    28,698.80
    -309.30 (-1.07%)
     
  • CRUDE OIL

    59.44
    +0.12 (+0.20%)
     
  • GOLD FUTURES

    1,742.70
    -2.10 (-0.12%)
     
  • DOW

    33,800.60
    +297.00 (+0.89%)
     
  • BTC-GBP

    43,894.52
    +602.92 (+1.39%)
     
  • CMC Crypto 200

    1,235.89
    +8.35 (+0.68%)
     
  • ^IXIC

    13,900.19
    +70.89 (+0.51%)
     
  • ^FTAS

    3,949.51
    -11.46 (-0.29%)
     

Global Self-Checkout Systems Market to Reach $6.2 Billion by 2027

ReportLinker
·22-min read

Abstract: - Global Self-Checkout Systems Market to Reach $6. 2 Billion by 2027. - Amid the COVID-19 crisis, the global market for Self-Checkout Systems estimated at US$3. 3 Billion in the year 2020, is projected to reach a revised size of US$6.

New York, April 07, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Self-Checkout Systems Industry" - https://www.reportlinker.com/p06051378/?utm_source=GNW
2 Billion by 2027, growing at a CAGR of 9.2% over the analysis period 2020-2027. Hardware, one of the segments analyzed in the report, is projected to record a 7.5% CAGR and reach US$2.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $983.2 Million, While China is Forecast to Grow at 8.7% CAGR
- The Self-Checkout Systems market in the U.S. is estimated at US$983.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.
- Services Segment to Record 9.4% CAGR
- In the global Services segment, USA, Canada, Japan, China and Europe will drive the 9.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$636.8 Million in the year 2020 will reach a projected size of US$1.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$720.4 Million by the year 2027.

- Select Competitors (Total 20 Featured) -

  • Crane Payment Innovations (CPI)

  • Diebold Nixdorf, Inc.

  • Fujitsu Ltd.

  • IBM Corporation

  • NCR Corporation

  • Olea Kiosks Inc.

  • PCMS Group Ltd.

  • Tesco PLC

  • Toshiba TEC Corporation




Read the full report: https://www.reportlinker.com/p06051378/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Psoriasis
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Psoriasis Treatment by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Psoriasis Treatment by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Interleukin
Blockers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Interleukin Blockers by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Interleukin Blockers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Topical
Corticosteroids by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Topical Corticosteroids by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Topical Corticosteroids
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Tumor Necrosis
Factor (TNF) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 11: World Historic Review for Tumor Necrosis Factor (TNF)
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Tumor Necrosis Factor
(TNF) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Vitamin D
Analogues by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 14: World Historic Review for Vitamin D Analogues by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Vitamin D Analogues by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Mechanism
of Actions by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 17: World Historic Review for Other Mechanism of Actions
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Other Mechanism of
Actions by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Oral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 20: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 22: World Current & Future Analysis for Topical by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 23: World Historic Review for Topical by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Topical by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 25: World Current & Future Analysis for Injectable by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 26: World Historic Review for Injectable by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Injectable by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Psoriasis Treatment
by Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 29: USA Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 30: USA 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Psoriasis Treatment
by Route Of Administration - Oral, Topical and Injectable -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Psoriasis Treatment by Route
Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

CANADA
Table 34: Canada Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 35: Canada Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 36: Canada 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 37: Canada Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

JAPAN
Table 40: Japan Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 41: Japan Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 42: Japan 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 43: Japan Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 44: Japan Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

CHINA
Table 46: China Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 47: China Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 48: China 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 49: China Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 50: China Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 51: China 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

EUROPE
Table 52: Europe Current & Future Analysis for Psoriasis
Treatment by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2020 through 2027 and % CAGR

Table 53: Europe Historic Review for Psoriasis Treatment by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Psoriasis Treatment by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 55: Europe Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 56: Europe Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 57: Europe 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 58: Europe Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 59: Europe Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 60: Europe 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

FRANCE
Table 61: France Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 62: France Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: France 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 64: France Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: France Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 66: France 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

GERMANY
Table 67: Germany Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 68: Germany Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 69: Germany 15-Year Perspective for Psoriasis Treatment
by Mechanism of Action - Percentage Breakdown of Value Sales
for Interleukin Blockers, Topical Corticosteroids, Tumor
Necrosis Factor (TNF), Vitamin D Analogues and Other Mechanism
of Actions for the Years 2012, 2020 & 2027

Table 70: Germany Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 71: Germany Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 72: Germany 15-Year Perspective for Psoriasis Treatment
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

ITALY
Table 73: Italy Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 74: Italy Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 75: Italy 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 76: Italy Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Italy Historic Review for Psoriasis Treatment by
Route Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 78: Italy 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

UNITED KINGDOM
Table 79: UK Current & Future Analysis for Psoriasis Treatment
by Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 80: UK Historic Review for Psoriasis Treatment by
Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 81: UK 15-Year Perspective for Psoriasis Treatment by
Mechanism of Action - Percentage Breakdown of Value Sales for
Interleukin Blockers, Topical Corticosteroids, Tumor Necrosis
Factor (TNF), Vitamin D Analogues and Other Mechanism of
Actions for the Years 2012, 2020 & 2027

Table 82: UK Current & Future Analysis for Psoriasis Treatment
by Route Of Administration - Oral, Topical and Injectable -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 83: UK Historic Review for Psoriasis Treatment by Route
Of Administration - Oral, Topical and Injectable Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 84: UK 15-Year Perspective for Psoriasis Treatment by
Route Of Administration - Percentage Breakdown of Value Sales
for Oral, Topical and Injectable for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 85: Rest of Europe Current & Future Analysis for
Psoriasis Treatment by Mechanism of Action - Interleukin
Blockers, Topical Corticosteroids, Tumor Necrosis Factor (TNF),
Vitamin D Analogues and Other Mechanism of Actions -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 86: Rest of Europe Historic Review for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 87: Rest of Europe 15-Year Perspective for Psoriasis
Treatment by Mechanism of Action - Percentage Breakdown of
Value Sales for Interleukin Blockers, Topical Corticosteroids,
Tumor Necrosis Factor (TNF), Vitamin D Analogues and Other
Mechanism of Actions for the Years 2012, 2020 & 2027

Table 88: Rest of Europe Current & Future Analysis for
Psoriasis Treatment by Route Of Administration - Oral, Topical
and Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 89: Rest of Europe Historic Review for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 90: Rest of Europe 15-Year Perspective for Psoriasis
Treatment by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Topical and Injectable for the Years
2012, 2020 & 2027

ASIA-PACIFIC
Table 91: Asia-Pacific Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 92: Asia-Pacific Historic Review for Psoriasis Treatment
by Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 93: Asia-Pacific 15-Year Perspective for Psoriasis
Treatment by Mechanism of Action - Percentage Breakdown of
Value Sales for Interleukin Blockers, Topical Corticosteroids,
Tumor Necrosis Factor (TNF), Vitamin D Analogues and Other
Mechanism of Actions for the Years 2012, 2020 & 2027

Table 94: Asia-Pacific Current & Future Analysis for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: Asia-Pacific Historic Review for Psoriasis Treatment
by Route Of Administration - Oral, Topical and Injectable
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 96: Asia-Pacific 15-Year Perspective for Psoriasis
Treatment by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Topical and Injectable for the Years
2012, 2020 & 2027

REST OF WORLD
Table 97: Rest of World Current & Future Analysis for Psoriasis
Treatment by Mechanism of Action - Interleukin Blockers,
Topical Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 98: Rest of World Historic Review for Psoriasis Treatment
by Mechanism of Action - Interleukin Blockers, Topical
Corticosteroids, Tumor Necrosis Factor (TNF), Vitamin D
Analogues and Other Mechanism of Actions Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 99: Rest of World 15-Year Perspective for Psoriasis
Treatment by Mechanism of Action - Percentage Breakdown of
Value Sales for Interleukin Blockers, Topical Corticosteroids,
Tumor Necrosis Factor (TNF), Vitamin D Analogues and Other
Mechanism of Actions for the Years 2012, 2020 & 2027

Table 100: Rest of World Current & Future Analysis for
Psoriasis Treatment by Route Of Administration - Oral, Topical
and Injectable - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 101: Rest of World Historic Review for Psoriasis
Treatment by Route Of Administration - Oral, Topical and
Injectable Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Rest of World 15-Year Perspective for Psoriasis
Treatment by Route Of Administration - Percentage Breakdown of
Value Sales for Oral, Topical and Injectable for the Years
2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 44
Read the full report: https://www.reportlinker.com/p06051378/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001